Ultravist Side Effects
Generic Name: iopromide
Note: This page contains side effects data for the generic drug iopromide. It is possible that some of the dosage forms included below may not apply to the brand name Ultravist.
It is possible that some side effects of Ultravist may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to iopromide: injection solution
As well as its needed effects, iopromide (the active ingredient contained in Ultravist) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking iopromide, check with your doctor or nurse immediately:Less common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- chest pain
- feeling faint, dizzy, or lightheadedness
- feeling of warmth or heat
- flushing or redness of the skin, especially on the face and neck
- frequent strong or increased urge to urinate
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- bluish lips or skin
- chest discomfort or tightness
- decreased frequency or amount of urination
- difficult or painful urination
- difficulty breathing
- excessive thirst
- fever or chills
- nausea or vomiting
- noisy breathing
- pain or discomfort in the arms, jaw, back, or neck
- pale skin at injection site
- irregular heartbeat
- tingling of the hands or feet
- unusual tiredness or weakness
- unusual weight gain or loss
- Blistering, peeling, or loosening of the skin
- bloody urine
- blue lips and fingernails
- coughing that sometimes produces a pink frothy sputum
- difficult, fast, noisy breathing, sometimes with wheezing
- difficulty with swallowing or sore throat
- dilated neck veins
- extreme fatigue
- irregular breathing
- joint or muscle pain
- loss of appetite
- lower back or side pain
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- red, irritated eyes
- red skin lesions, often with a purple center
- sensitivity to heat
- skin rash, hives, or itching
- sores, ulcers, or white spots in the mouth or on the lips
- swelling of the face, fingers, feet, or lower legs
- trouble sleeping
Some iopromide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:Less common
- Change in taste
- changes in vision
- loss of taste
- Abdominal or stomach discomfort or pain
- acid or sour stomach
- belching or passing of gas
- body aches or pain
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- difficulty with moving
- dry mouth
- excessive muscle tone
- general feeling of discomfort or illness
- lack of coordination
- loss of strength or energy
- muscle tension or tightness
- sleepiness or unusual drowsiness
- tender, swollen glands in the neck
- voice changes
- Bigger, dilated, or enlarged pupils (black part of the eye)
- burning, dry, or itching eyes
- continuing ringing or buzzing or other unexplained noise in the ears
- discharge, excessive tearing
- feeling of constant movement of self or surroundings
- headache, severe and throbbing
- hearing loss
- increased sensitivity of the eyes to light
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- sensation of spinning
For Healthcare Professionals
Applies to iopromide: injectable solution
Cardiovascular side effects have included vasodilation (2.6%), chest pain (1.6%), complete atrioventricular block (less than 1%), bradycardia (less than 1%), ventricular extrasystole (less than 1%), coronary artery thrombosis (less than 1%), flushing (less than 1%), hypertension (less than 1%), hypotension (less than 1%), peripheral vascular disorder (less than 1%), syncope (less than 1%), and vascular anomaly (less than 1%). Postmarketing reports have included cardiac arrest, ventricular fibrillation, atrial fibrillation, tachycardia, palpitations, congestive heart failure, myocardial infarction, angina pectoris and vasospasm.
Dermatologic side effects have included erythema (less than 1%), pruritus (less than 1%), rash (less than 1%), urticaria (less than 1%), and fixed eruptions. Postmarketing reports have included Stevens-Johnson Syndrome and skin discoloration.
Endocrine side effects have included postmarketing reports of hyperthyroidism, thyrotoxic crisis, and hypothyroidism.
Gastrointestinal side effects have included nausea (3.7%), vomiting (1.9%), abdominal discomfort (less than 1%), abdominal pain (less than 1%), upper abdominal pain (less than 1%), constipation (less than 1%), diarrhea (less than 1%), dry mouth (less than 1%), dyspepsia (less than 1%), gastrointestinal disorder (less than 1%), gastrointestinal pain (less than 1%), increased salivation (less than 1%), stomach discomfort (less than 1%), and rectal tenesmus (less than 1%). Postmarketing reports have included dysphagia and swelling of salivary glands.
General side effects have included pain (1.4%), asthenia (less than 1%), chest discomfort (less than 1%), chills (less than 1%), excessive thirst (less than 1%), feeling hot (less than 1%), hyperhidrosis (less than 1%), malaise (less than 1%), peripheral edema (less than 1%), and pyrexia (less than 1%).
Genitourinary side effects have included urinary urgency (1.8%), dysuria (less than 1%), urinary retention (less than 1%) and postmarketing reports of hematuria.
Hypersensitivity reactions have included facial edema (less than 1%). Postmarketing reports have included anaphylactoid reaction (including fatal cases), respiratory arrest, anaphylactoid shock, angioedema, laryngeal edema, laryngospasm, bronchospasm, and hypersensitivity.
Local side effects have included injection site and infusion site reactions (hemorrhage, hematoma, pain, edema, erythema, rash) (3.7%) and extravasation (less than 1%).
Metabolic side effects have included diabetes insipidus.
Laboratory abnormalities have included increased blood lactate dehydrogenase (less than 1%), increased blood urea (less than 1%), increased hemoglobin (less than 1%), and increased white blood cell count (less than 1%).
Musculoskeletal side effects have included back pain (1.9%), arthralgia (less than 1%), musculoskeletal pain (less than 1%), myasthenia (less than 1%), neck pain (less than 1%), pain in extremity (less than 1%), joint disorder (effusion), muscle cramps, and postmarketing reports of compartment syndrome in case of extravasation.
Nervous system side effects have included headache (4%), dysgeusia (1.3%), agitation (less than 1%), confusion (less than 1%), convulsion (less than 1%), dizziness (less than 1%), hypertonia (less than 1%), hypesthesia (less than 1%), incoordination (less than 1%), neuropathy (less than 1%), somnolence (less than 1%), speech disorder (less than 1%), tremor (less than 1%), paresthesia (less than 1%), visual field defect (less than 1%), migraine, and brain edema. Postmarketing reports have included vertigo, tinnitus cerebral ischemia/infarction, paralysis, paresis, transient cortical blindness, aphasia, coma, unconsciousness, amnesia, hypotonia, and aggravation of myasthenia gravis symptoms.
Ocular side effects have included abnormal vision (1.1%) and conjunctivitis. Postmarketing reports have included mydriasis and lacrimation disorder.
Psychiatric side effects have included anxiety (less than 1%).
Renal side effects have included renal pain (less than 1%) and postmarketing reports of renal failure.
Respiratory side effects have included asthma (less than 1%), apnea (less than 1%), increased cough (less than 1%), dyspnea (less than 1%), hypoxia (less than 1%), pharyngeal edema (less than 1%), pharyngitis (less than 1%), pleural effusion (less than 1%), pulmonary hypertension (less than 1%), respiratory disorder (less than 1%), sore throat (less than 1%), and epistaxis. Postmarketing reports have included pulmonary edema, acute respiratory distress syndrome, and asthma.
More about Ultravist (iopromide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.